Stoke Therapeutics, Inc.
STOK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001623526
In the last 90 days, Stoke Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 197 institutions reported holding it in 13F filings for Q2 2026, worth $2.53B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.26M in total
- 6
- 13F holdersQ2 2026, +1 vs. previous quarter
- 197
- 13F valueReported value at the end of Q2 2026
- $2.53B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding STOK, Q2 2026
No superinvestor reported holding STOK at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Stoke Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)4:17 PM ET | Sep 1 | 2 days | Ticho BarryCHIEF MEDICAL OFFICER | SSale | −5.54K | $30.67 | −$170.1K | −21.6%20.1K after | 2 lots10b5-1 |
| Aug 18, 2026 (view filing)8:29 PM ET | Aug 18 | Same day | Ticho BarryCHIEF MEDICAL OFFICER | SSale | −4.77K | $32.03 | −$152.7K | −15.7%25.7K after | 2 lots |
| Aug 18, 2026 (view filing)8:28 PM ET | Aug 18 | Same day | Kaye Edward M. MDDirector | SSale | −12.6K | $32.03 | −$402.5K | −9.2%124.6K after | 2 lots |
| Aug 18, 2026 (view filing)8:27 PM ET | Aug 18 | Same day | Allan JonathanGENERAL COUNSEL & CORP SEC | SSale | −2.86K | $32.03 | −$91.6K | −11.9%21.2K after | 2 lots |
| Aug 5, 2026 (view filing)4:17 PM ET | Aug 3 | 2 days | Ticho BarryCHIEF MEDICAL OFFICER | SSale | −7.18K | $29.04 | −$208.4K | −26.0%20.4K after | 2 lots10b5-1 |
| Jul 6, 2026 (view filing)4:10 PM ET | Jul 1 | 5 days | Ticho BarryCHIEF MEDICAL OFFICER | SSale | −7.23K | $32.66 | −$236.1K | −20.8%27.6K after | 2 lots10b5-1 |
| Jun 18, 2026 (view filing) | Jun 16 | 2 days | Allan JonathanGENERAL COUNSEL & CORP SEC | SSale | −1.46K | $29.95 | −$43.6K | −7.5%18.1K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Ticho BarryCHIEF MEDICAL OFFICER | SSale | −1.79K | $30.58 | −$54.9K | −4.9%34.8K after | 10b5-1 |
| May 5, 2026 (view filing) | May 1 | 4 days | Ticho BarryCHIEF MEDICAL OFFICER | SSale | −2.24K | $32.79 | −$73.5K | −5.8%36.6K after | 10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Ticho BarryCHIEF MEDICAL OFFICER | SSale | −1.84K | $32.66 | −$60.0K | −4.5%38.9K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Stoke Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,877,357 | $192.3M | 0.00% | +491,643+9.1% | Added |
| RTW Investments, LP | 5,623,525 | $184.0M | 1.57% | 00.0% | Unchanged |
| FMR LLC | 5,313,100 | $173.8M | 0.01% | −70,566−1.3% | Reduced |
| Lynx1 Capital Management LP | 4,038,404 | $132.1M | 15.27% | −725,269−15.2% | Reduced |
| Redmile Group, LLC | 3,945,920 | $129.1M | 8.67% | −218,200−5.2% | Reduced |
| Wellington Management Group LLP | 3,519,301 | $115.2M | 0.02% | +423,601+13.7% | Added |
| Morgan Stanley | 3,452,795 | $113.0M | 0.01% | +29,515+0.9% | Added |
| Baker Bros. Advisors LP | 3,336,697 | $109.2M | 0.55% | 00.0% | Unchanged |
| Toronto Dominion Bank | 3,173,258 | $103.8M | 0.17% | 00.0% | Unchanged |
| State Street Corp | 2,852,240 | $93.3M | 0.00% | +575,728+25.3% | Added |